Revised Consensus Clinical Trial Response Criteria by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology

Invasive fungal diseases remain a significant cause of patient morbidity and mortality. Improvement in clinical outcomes have been the result of progress in risk stratification, diagnostics, adjunctive care, antifungal therapy, and/or prophylaxis. Yet significant challenges remain, requiring the development of novel treatment strategies. Outcome evaluation in most mycology clinical trials is currently based on consensus criteria published in 2008. However, advances in diagnosis and management of various mycoses and the ever-expanding population of patients at risk necessitate a revision and refinement of these criteria. Appropriate categorization of antifungal treatment response is crucial in assessing the effects of new therapeutic interventions. An international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened to update the current outcome evaluation criteria. The panel achieved consensus on updated guidelines for assessing treatment responses and defining study outcomes in clinical trials of aspergillosis and other mold diseases, invasive candidiasis, cryptococcosis, and dimorphic fungi in both adults and children. This summary manuscript provides details on the methods, outlines key changes in the criteria, and discusses the next steps and areas for future research.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2026-11-17
DOI
https://doi.org/10.1093/cid/ciag579
Citations
1
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
3.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Revised Consensus Clinical Trial Response Criteria by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology

Neil A. R. Gow, Tihana A. Bicanic, Carolynn Thomas Jones, Ana Alastruey‐Izquierdo et al.
1 citations
Clinical Infectious Diseases
Antifungal resistance and susceptibility
3.05
article

Revised Consensus Clinical Trial Response Criteria by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology

Neil A. R. Gow, Tihana A. Bicanic, Carolynn Thomas Jones, Ana Alastruey‐Izquierdo, David R. Boulware, Jean‐Pierre Gangneux, Monica A. Slavin, John R. Perfect, Dimitrios P. Kontoyiannis, Sevtap Arıkan-Akdağlı, Marisa H. Miceli, Martin Hoenigl, Luis L. Ostrosky-Zeichner, Cornelia Lass‐Flörl, George R. Thompson, Oliver A. Cornely, Patricia Muñóz, Johan A. Maertens, José A. Vázquez, Peter G. Pappas
article en
1 citations

Abstract

Invasive fungal diseases remain a significant cause of patient morbidity and mortality. Improvement in clinical outcomes have been the result of progress in risk stratification, diagnostics, adjunctive care, antifungal therapy, and/or prophylaxis. Yet significant challenges remain, requiring the development of novel treatment strategies. Outcome evaluation in most mycology clinical trials is currently based on consensus criteria published in 2008. However, advances in diagnosis and management of various mycoses and the ever-expanding population of patients at risk necessitate a revision and refinement of these criteria. Appropriate categorization of antifungal treatment response is crucial in assessing the effects of new therapeutic interventions. An international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened to update the current outcome evaluation criteria. The panel achieved consensus on updated guidelines for assessing treatment responses and defining study outcomes in clinical trials of aspergillosis and other mold diseases, invasive candidiasis, cryptococcosis, and dimorphic fungi in both adults and children. This summary manuscript provides details on the methods, outlines key changes in the criteria, and discusses the next steps and areas for future research.

Clinical Infectious Diseases
Universidad Complutense de Madrid (ES), University of Minnesota (US), The University of Texas MD Anderson Cancer Center (US), Innsbruck Medical University (AT), Inserm (FR), The University of Melbourne (AU), Duke University (US), University of Cologne (DE), Universität Innsbruck (AT), Medical University of Graz (AT), University of Exeter (GB), Augusta University (US), University of Michigan (US), Universitair Ziekenhuis Leuven (BE), Peter MacCallum Cancer Centre (AU), Instituto de Salud Carlos III (ES), Hospital General Universitario Gregorio Marañón (ES), University of Alabama at Birmingham (US), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), Institut de Recherche en Santé, Environnement et Travail (FR), Centro de Investigación Biomédica en Red (ES), German Center for Infection Research (DE), BioTechMed-Graz (AT), Duke Medical Center (US), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE), University Hospital Cologne (DE), Centre Hospitalier Universitaire de Rennes (FR), University of California Davis Medical Center (US), MRC Centre for Medical Mycology (GB), UAB Medicine (US), City St George's, University of London (GB), Centro de Investigación Biomédica en Red Enfermedades Infecciosas (ES), Instituto de Investigación Sanitaria Gregorio Marañón (ES), The Ohio State University (US), Université de Rennes (FR), Hacettepe University (TR), University of California, Davis (US), The University of Texas Health Science Center at Houston (US), KU Leuven (BE)
National Institute for Health and Care Research
Good health and well-being
Openalex Percentile: Top 17%
Antifungal resistance and susceptibility
3.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon